Manufacturing roundup: WuXi continues its expansion drive with another plant opening in Changzhou; Swiss biotech nets another acquisition
The CDMO WuXi STA has been rapidly expanding over the past year, and its next opening will expand its offering in the peptide sector.
WuXi has opened two new large-scale oligonucleotide and peptide manufacturing facilities at its campus in Changzhou, China, according to the company. However, the financial and employment details have not been disclosed to Endpoints News.
The new 30,000 square-foot facility for oligonucleotide development and manufacturing contains four oligonucleotide production lines and more than 20 small- to mid-scale production lines that should increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.